CDMO Rentschler Biopharma has held a celebration, under the motto "Together We Build," of the strong progress of its US site in Milford, Massachusetts.
Since 2019, the company has upgraded its facility into a cutting-edge, multi-product site. The newest manufacturing line is now fully operational, representing the largest expansion in Rentschler Biopharma's more than 150-year history. As a result, the company says, an increasing number of client projects are being successfully initiated and delivered.
The event recognised the site's achievements to date and highlighted its importance within Rentschler Biopharma's global network.
The programme included remarks from the supervisory board and company leadership, including Dr Nikolaus Rentschler and members of the Executive Committee.
Massachusetts State Representative Brian W. Murray presented Rentschler Biopharma with a citation recognising the company's contributions to the region's biotechnology ecosystem.
"The growth and success of Rentschler Biopharma to what is now a state-of-the-art, multi-product facility with a greatly expanded manufacturing cleanroom space in Milford has been nothing short of remarkable," said State Representative Brian W. Murray (D. Milford).
"It has created tremendous economic and employment opportunities throughout the Greater Milford area, as well as provided a caring corporate citizen with increasingly deep roots that will continue to benefit the entire community."
Dr Uwe Buecheler, Interim CEO, commented: "At Rentschler Biopharma, we are committed to advancing medicine to save lives—together."
'Together We Build' reflects how we support our clients by delivering reliably at every step of their molecule's journey. With our expanded US footprint, we combine deep technical expertise, a proven track record of high‑quality execution and the long‑term stability of our family‑owned company.
"This site is an integral part of our global network, enabling seamless continuity from early development through commercial supply. We will continue building on this strong foundation, together with our clients and our people, to bring innovative therapies to patients who need them."
Tom Roberts, President of Rentschler Biopharma Inc. and General Manager US, added: "Our Milford site has entered a new phase of growth."
"We are onboarding diverse client programmes, advancing late‑stage projects and supporting partners from across the world who trust us with their most critical molecules."
What sets us apart is our hands‑on scientific expertise and the way our teams work side‑by‑side with clients to design tailored solutions that keep programmes moving forward with speed and confidence.
The new production line at the Milford, MA site is the largest expansion in Rentschler Biopharma's 150-year history, highlighting the US as a key part of the company's commercial strategy.
Fully operational since 2024, it adds 22,000 square feet of cleanroom space and enhances global cGMP capacity with four 2000 L single-use bioreactors.
This facility supports a variety of therapeutics across multiple disease areas, including oncology, haematology, musculoskeletal, cardiovascular and organ failure. In the past two years, seven new products have been introduced, including those in or completed Process Performance Qualification (PPQ).